Skip to main content
OpenTrials
Completed

NCT Number: NCT00345969

Exercise and Testosterone Therapy in Elderly Men With Physical Frailty

The primary aim of this study is to determine, in hypogonadal older men with physical frailty, whether exercise training combined with testosterone replacement therapy can improve skeletal muscle strength, and lean mass, to a greater degree than exercise training alone.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 3

Primary location

Washington University School of Medicine

St Louis, Missouri, 63110, United States

About this study

Decreases in physical abilities, including losses of strength, endurance, balance, and coordination are major causes of disability and loss of independence in older men. Such individuals are at high risk for injurious falls, hospitalization, and use of supportive services. Age-associated testosterone deficiency may contribute to deficits in muscle mass and strength that are common in this patient population.

The primary aim of this study is to determine, in hypogonadal older men with physical frailty, whether six months of exercise training combined with testosterone replacement therapy can improve skeletal muscle mass and skeletal muscle strength, to a greater degree than six months of exercise training alone.

Secondary study aims are to determine in hypogonadal older men with physical frailty, whether six months of exercise training combined with testosterone replacement therapy can improve physical function, bone mineral density, and quality of life, to a greater degree than six months of exercise training alone.

Comparison: Men age 65 years and older who meet criteria for physical frailty and have a serum testosterone level below 350 ng/dl are randomly assigned to one of two groups: 1) transdermal testosterone replacement therapy + supervised exercise training for six months vs. 2) inactive placebo gel + supervised exercise training for six months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male, age 65 years and older
  • Total serum testosterone level < 350 ng/dl
  • Total Modified Physical Performance Test Score <28

Exclusion criteria

  • Inability to walk 50 feet independently
  • Current use of estrogen, progestin, or androgen containing compound
  • Diagnosis of dementia of severity sufficient to interfere with informed consent or compliance with the protocol, or a score of 11 or greater on the Short Blessed Test of Orientation, Memory and Concentration
  • Visual or hearing impairments that interfere with following directions
  • Cardiopulmonary disease (recent MI, unstable angina or CHF, etc.), neuromuscular impairments, or unstable medical condition that would contraindicate progressive resistance exercise training
  • History of prostate cancer or hormone dependent neoplasia
  • PSA level > 4 ng/ml
  • Serum liver transaminase levels of greater than 2 standard deviations above normal
  • Use of drugs for osteoporosis for less than 1 year
  • Current participation in a vigorous exercise or weight-training program more than once per week
  • History of sleep apnea requiring use of CPAP
  • Uncontrolled thyroid disease
  • Diagnosis of cancer within the past 5 years other than superficial skin cancer (squamous or basal cell)
  • hematocrit > 50%
  • AUA symptom score > 16.
  • History of alcohol or substance abuse
  • Presence of severe facial acne
  • Active symptoms of depression with GDS score > 5 and symptoms severe enough to cause >5% weight loss in previous 3 months or interfere with research assessments

Treatment and study plan

Transdermal Testosterone gel (1%)

Drug

Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.

Other names: Androgel

Supervised exercise training

Behavioral

Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.

Primary outcomes

  1. Mean Change in Total Lean Body Mass

    Time frame: Baseline and Six Months

    Total Lean Mass measured by Dual X-ray Absorptiometry (DXA)

  2. Change in Skeletal Muscle Strength by 1-RM

    Time frame: Baseline and Six Months

    One-repetition maximum strength for leg extension

Secondary outcomes

  1. Change in Isokinetic Leg Extension Torque at 0 Deg/Sec

    Time frame: Baseline and Six Months

    Leg Extension Torque measured with Cybex dynamometer at 0 deg/sec

  2. Change in Leg Extension Torque at 60 Deg/Sec

    Time frame: Baseline and Six Months

    Leg Extension Torque measured with Cybex dynamometry at 60 deg/sec

  3. Change in Total Body Fat Mass

    Time frame: Baseline and Six Months

    Total Body Fat Mass as measured by DXA

  4. Change in Femoral Bone Mineral Density (BMD)

    Time frame: Baseline and Six Months

    Femoral Bone Mineral Density measured with Dual X-ray Absorptiometry (DXA)

  5. Change in Total Modified Physical Performance (mPPT) Score

    Time frame: Baseline and Six Months

    The Modified Physical Performance Test (mPPT) is a direct observational test that assesses multiple dimensions of physical function (basic and complex activities of daily living [ADL]) with different levels of difficulty. The test consists of 9 performance tasks. The total score range is 0-36 (min-max), with higher scores indicating better performance. Sub-scores are assigned for each of 9 item tasks; sub-score range is 0-4 (min-max) with higher scores indicating better performance. The sub-scores are summed to compute the total score.

  6. Change in Serum Testosterone Level

    Time frame: Baseline and Six Months

    Total Serum Testosterone Level (ng/mL)

Other outcomes

  1. Change in Serum Prostate Specific Antigen (PSA) Level

    Time frame: Baseline and Six Months

  2. Change in Hematocrit

    Time frame: Baseline and Six Months

    Percentage of the volume of whole blood composed of Red Blood Cells

  3. Change in Serum Total Cholesterol Level

    Time frame: Baseline and Six Months

  4. Change in Serum HDL Cholesterol Level

    Time frame: Baseline and Six Months

  5. Change in Serum LDL Cholesterol Level

    Time frame: Baseline and Six Months

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Collaborators

  • Solvay Pharmaceuticals

Registry information

Important dates

Study start
2004
Primary completion
2009
Study completion
2009
First posted
Jun 29, 2006
Registry last updated
Feb 22, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.